CareLit · DOI-Nachweis · Nuklearmedizin - NuclearMedicine
CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges
DOI 10.1055/a-2194-9965
Bibliografische Angaben
Nachweis in CareLit
Autor:innenRudolf Werner, Alexander Haug, Christian Buske, Simon Heidegger, Anna L. Illert, Florian Bassermann, Peter Herhaus, Andreas Buck, Johannes Duell, Max S Topp, Sabrina Kraus, Hermann Einsele, Constantin Lapa, Markus Raderer, Georg Lenz, Stefan Habringer, Bastian von Tresckow, Ulrich Keller
ZeitschriftNuklearmedizin - NuclearMedicine
Ausgabe02/2024
Jahrgang / SeitenJg. 63 · S. 57-61
Kernaussage aus der Literatur
Abstract-Vorschau
AbstractC-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in a multitude of cancers, including neoplasms of hematopoietic origin. This feature can be leveraged by a theranostic approach, which provides a read-out of the actual CXCR4 expression in vivo, followed by CXCR4-targeted radioligand therapy (RLT) exerting anti-cancer as well as myeloablative efficacy. In a recent meeting of hematooncology and nuclear…
Zitieren
Zitierempfehlung
Rudolf Werner, Alexander Haug, Christian Buske, Simon Heidegger, Anna L. Illert, Florian Bassermann, Peter Herhaus, Andreas Buck, Johannes Duell, Max S Topp, Sabrina Kraus, Hermann Einsele, Constantin Lapa, Markus Raderer, Georg Lenz, Stefan Habringer, Bastia… (2024) CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges. Nuklearmedizin - NuclearMedicine, 63 (02), 57-61. https://doi.org/10.1055/a-2194-9965
Mit CareLit weiterarbeiten